Biblio
Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation. Ann Hematol. 2023.
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Ann Hematol. 2023.
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning. Expert Opin Biol Ther. 2023:1-9.
The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic. Support Care Cancer. 2023;31(6):350.
Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts. Biol Blood Marrow Transplant. 2019.
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opin Pharmacother. 2019:1-10.
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res. 2015;2015:968212.
. High-dose chemotherapy for germ cell tumors: do we have a model?. Expert Opin Biol Ther. 2014:1-12.
.